Contact Congress about S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Medicare would cover some FDA-priority medical devices sooner. The bill creates a 4-year temporary coverage period while Medicare decides long-term payment rules.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Ensuring Patient Access to Critical Breakthrough Products Act of 2025 is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.

Latest action on S. 1717: Read twice and referred to the Committee on Finance.

Who this affects: This bill mainly affects Medicare patients who might need new medical devices for serious health problems. It also affects doctors and hospitals that use those devices, companies that make them, and the Centers for Medicare & Medicaid Services, which runs Medicare coverage rules. Congress and the public would get yearly reports showing how often this new path is used.

Why this matters: New medical devices can reach patients slowly if Medicare coverage is unclear. This bill tries to make that path faster and more predictable for devices the FDA has already treated as high priority. That could help patients with serious conditions, but the real effect depends on how many devices qualify and how Medicare uses its safety limits. It also raises cost questions because the bill does not say how much the new coverage could add to Medicare spending.

Key provisions in S. 1717

• Medicare would get a formal "breakthrough device" label. A device could qualify only after FDA clearance or approval and FDA priority review under the FDA breakthrough device law.
• The temporary Medicare coverage window would last 4 years. It would start on the day the Department of Health and Human Services gives the device breakthrough status.
• Medicare could still deny or limit payment during that 4-year window. That could happen if doctors use the device outside its FDA-approved label, or if clinical data show the risks are too high for Medicare patients.
• The Department of Health and Human Services would have to act within 6 months. That deadline applies after a manufacturer files a request for breakthrough device status.
• If the agency says no, it must explain why. It must name the specific rules the device did not meet.

How Modern Action helps you take action on S. 1717

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1717

What is S. 1717?

Medicare would cover some FDA-priority medical devices sooner. The bill creates a 4-year temporary coverage period while Medicare decides long-term payment rules.

How do I support or oppose S. 1717?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1717?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 1717?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.